According to Glenmark Pharmaceuticals, China’s National Medical Products Administration (NMPA) has approved Ryaltris olopatadine hydrochloride / mometasone furoate nasal spray for the treatment of allergic rhinitis. Grand Pharmaceuticals, which acquired the Chinese rights to Ryaltris in 2019, will commercialize the nasal spray in China. Ryaltris has previously been approved in numerous markets, including the US, Canada, the EU and UK, Australia, and Russia.
Glenmark Pharmaceuticals President and Business Head, Europe and Emerging Markets, Christoph Stoller commented, “The approval of Ryaltris in China is a significant step in expanding our specialty respiratory portfolio. China is a priority market for Glenmark, and together with Grand Pharmaceuticals, our focus is on enabling access to this treatment for patients and healthcare professionals.”
Read the Glenmark Pharmaceuticals press release
